Rafael Holdings, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Rafael Holdings, Inc. (NYSE:RFL) is a clinical-stage biotechnology holding company that invests in and develops therapies for difficult-to-treat diseases, including novel cancer metabolism inhibitors and treatments for rare genetic disorders; it operates through healthcare, infusion technology, and real estate segments with activities in the United States and Israel. Founded in 2017 and headquartered in Newark, New Jersey, the company holds a 100% interest in Cyclo Therapeutics, LLC, which advances Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) in the fully enrolled Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1, with 48-week interim data expected mid-2025; it maintains investments in Cornerstone Pharmaceuticals developing CPI-613 (devimistat) for solid tumors and acute myeloid leukemia, LipoMedix Pharmaceuticals with liposome-delivered oncology therapies, Day Three Labs reimagining cannabis products via pharmaceutical-grade technology like Unlokt, Rafael Medical Devices for orthopedic instruments, and commercial real estate assets. In March 2025, Rafael Holdings completed its merger with Cyclo Therapeutics following shareholder approval, integrating the rare disease asset and shifting strategic focus toward its commercialization while curtailing early-stage development; the company closed a $25 million rights offering in June 2025 to fund Trappsol Cyclo advancement, issued 1,078,796 warrants expiring December 2025 as part of the merger, and announced CEO Bill Conkling's transition amid strengthened emphasis on Trappsol Cyclo, with recent abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism and preliminary Phase 3 sub-study data showing stabilization in young NPC1 patients.
Sekur Private Data Appoints Special Operations Communications Chief Master Sergeant (Ret.) Rafael Beltran to Its OpsTech Special Advisory Board
AuMEGA Metals Appoints Rafael Gradim as President
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
Heineken names Rafael Oliveira as CEO
Heineken N.V. announces nomination of Rafael Oliveira as Chief Executive Officer
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”
Critical Comparison: Elite Pharmaceuticals (OTCMKTS:ELTP) versus Rafael (NYSE:RFL)
Keurig Dr Pepper Acquires JDE Peet's and Announces Rafael Oliveira as CEO of Future Global Coffee Co.
Keurig Dr Pepper Acquires JDE Peet's and Announces Rafael Oliveira as CEO of Future Global Coffee Co.
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
T3 Defense Brings in Former Rafael and Avnon Leadership to Lead Business Operations
Analyzing Rafael (NYSE:RFL) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Mt. San Rafael Hospital Selects Oracle Health To Optimize Financial Performance, Enhance Patient Care
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
R2S receives $1.25 billion Tamir production contract for facility in Camden, Arkansas
Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States
Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results